School of Pharmacy and Medical Sciences, Menzies Health Institute Queensland, Griffith University, Gold Coast, Australia.
Mater Research Institute-The University of Queensland, Brisbane, Australia.
J Child Adolesc Psychopharmacol. 2023 Sep;33(7):279-286. doi: 10.1089/cap.2023.0016. Epub 2023 Jul 27.
Prescription of second-generation antipsychotics (SGAs) in youths is rapidly increasing globally, despite the potential for significant adverse effects and long-term health consequences. A known adverse reaction resulting from SGAs is metabolic syndrome (MS). Youths exposed to antipsychotics are at higher risk than adults for adverse drug reactions, including adverse events such as MS (with weight gain as the most significant adverse outcome) and other long-term endocrinological abnormalities. This study aimed to explore the experiences of young patients on factors impacting barriers to metabolic monitoring of SGAs and the strategies to address those barriers thereby providing further guidance on policy and service delivery. Semi-structured interviews were conducted with patients (youths who were prescribed SGAs) who attended Child and Youth Mental Health Services. The interviews focused on barriers to monitoring and strategies to enhance rates of monitoring that could be customized across study sites. Young patients revealed that none of them had any concerns or objections to receiving anthropometric metabolic measurements. However, they seemed concerned to undergo blood tests as part of the metabolic monitoring process. Specifically, youths cited their fear of the needles as barrier to undergo the required blood tests. Youths have also reported that their dislike to healthy foods and exercise being the most common challenge they face while trying to engage in a healthy lifestyle to manage the SGAs resulted weight gain. Prescribers are recommended to actively engage young patients about the expected SGAs-induced adverse effects, the importance of conducting metabolic monitoring, and how to prevent and minimize the expected adverse effects from the start of initiating SGAs. This could be a vital step toward a successful treatment as the insight of youths into the details of the chosen treatment can play a significant role into treatment adherence and recovery.
处方第二代抗精神病药物(SGAs)在全球范围内迅速增加,尽管存在潜在的重大不良反应和长期健康后果。SGAs 导致的已知不良反应是代谢综合征(MS)。与成年人相比,接触抗精神病药物的青少年发生药物不良反应的风险更高,包括代谢综合征(体重增加是最显著的不良后果)和其他长期内分泌异常等不良事件。本研究旨在探讨年轻患者对影响 SGA 代谢监测障碍的因素的体验,以及解决这些障碍的策略,从而为政策和服务提供进一步的指导。 对参加儿童和青年心理健康服务的患者(服用 SGA 的年轻人)进行了半结构式访谈。访谈重点关注监测障碍和提高监测率的策略,这些策略可以在各个研究地点进行定制。 年轻患者表示,他们对接受人体测量代谢测量没有任何担忧或反对。然而,他们似乎对作为代谢监测过程一部分的血液测试感到担忧。具体来说,年轻人提到他们害怕接受所需的血液测试是因为针头。年轻人还报告说,他们不喜欢健康食品和运动,这是他们在尝试健康生活方式来控制 SGA 导致体重增加时面临的最常见挑战。 建议开处方者积极与年轻患者讨论预期的 SGA 诱导的不良反应、进行代谢监测的重要性以及如何从开始使用 SGA 时预防和最小化预期的不良反应。这可能是成功治疗的重要一步,因为年轻人对所选治疗的详细了解可以在治疗依从性和康复方面发挥重要作用。